Eczema Pipeline Insight and Clinical Trial Phases Report | 100+ Companies and 100+ Drugs

DelveInsight's, "Eczema Pipeline Insight, 2023" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the Eczema pipeline drug profiles, including Eczema clinical trial and nonclinical stage products. It also covers the Eczema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Eczema Pipeline Report

• DelveInsight's Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for eczema treatment.

• The leading Eczema Companies include Kymab, BiomX, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Ichnos Sciences, AOBiome, Kangstem Biotech, Devonian, VYNE therapeutics, BenevolentAI, Amytrx Therapeutics, Asana BioSciences, RAPT Therapeutics, Celgene Corporation, Shaperon, Allakos, KeyMed Biosciences, Ribon Therapeutics, Pfizer, Amgen, Evelo Biosciences, Novartis Pharmaceuticals, Oneness Biotech, Aclaris Therapeutics, Biosion, LEO Pharma, Principia Biopharma, Reistone Biopharma Company Limited, Botanix Pharmaceuticals, Qurient, Eli Lilly and Company, Suzhou Connect Biopharmaceuticals, Hoth Therapeutics, Kymera Therapeutics, KoBioLabs, and others.

• Promising Eczema Pipeline Therapies include Amlitelimab, BX 005, LP 0145, GSK 1070806, AR 100, SCM AGH, SCD-044, BBI 02, Lebrikizumab, Benralizumab, UCB9741, ARQ-151, si-544, KHK-4083, ISB-830, B 244, FURESTEM-AD inj, PUR-0110, UCB-1381, FMX-114, BEN 2293, AMTX 100, Gusacitinib, RPT 193, CC 93538, HY-209, AK 002, CM 326, CM 310, RBN 3143, PF-07242813, Apremilast, EDP 1815, MEDI3506, Etrasimod, CMK 389, FB 825, ATI-1777, BSI 045B, LEO-152020, Rilzabrutinib, SHR0302, PRN-473, BTX-1204A, Q-301, Lebrikizumab, CBP 201, BioLexa, KT 474, KBL 697, and others

• The Eczema Companies and academics are working to assess challenges and seek opportunities that could influence Eczema R&D. The Eczema pipeline therapies under development are focused on novel approaches to treat/improve Eczema.

Discover the recent advances in eczema treatment drugs and Eczema Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Eczema Treatment Landscape

• In August 2022, UNION therapeutics announced enrollment of the first patient in ADESOS Phase II b study of orismilast MR tablet in patients with atopic dermatitis. The purpose of the study is to identify the appropriate dose regimen for Phase III studies.

• In August 2022, Lynk Pharmaceuticals Co., announced that its innovative drug LNK01004, had been approved by National Medical Products Administration (NMPA) for clinical trials in the treatment of atopic dermatitis (AD).

• In June 2022, ASLAN Pharmaceuticals announced that it had initiated a research collaboration with Dr. Shawn Kwatra and Dr. Madan Kwatra from Duke University Medical Center to investigate the unique role of the IL-13Ra1 subunit, distinct from the role of other pathway components, in Type 2-mediated inflammatory diseases, specifically atopic dermatitis (AD).

• In May 2022, Brickell Biotech, Inc. announced that the first subjects were dosed in the single ascending dose ("SAD") portion of the Company's Phase 1 clinical trial evaluating BBI-02 in healthy adult subjects and patients with atopic dermatitis ("AD").

• In April 2022, Eli Lilly and Company announced that Lebrikizumab Combined with Topical Corticosteroids showed significant improvements in disease severity for Atopic Dermatitis. Lebrikizumab significantly improved several areas of great importance to patients with atopic dermatitis, including skin and itch, in a pivotal combination trial that met all primary and key secondary endpoints

• In February 2022, FDA accepted for priority review the supplemental biologics license application (sBLA) for dupilumab (Dupixent, Regeneron Pharmaceuticals, Sanofi) as an add-on maintenance treatment for children aged 6 months to 5 years with moderate to severe atopic dermatitis (AD).

Eczema Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection. Eczema is commonly known as the ""itch that rashes"" due to dry skin that leads to a rash as a result of scratching or rubbing. The most important treatment of eczema is skin hydration followed by topical steroids for flare-ups. The lifetime prevalence of atopic dermatitis is about 15-30% in children and 2-10% in adults. About 60% of cases will develop within the first year of life. The prevalence of atopic dermatitis is more common in rural rather than urban areas. This incidence which emphasizes the link to lifestyle and environment factors in the mechanisms of AD. Symptoms of eczema include: A red rash or red patches of skin, especially inside the folds of the elbows and knees, itching, dry skin, which possibly bleed.

Find out more about Eczema Treatment Drugs and Eczema Treatment Landscape @ https://www.delveinsight.com/sample-request/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Eczema Emerging Drugs

• Amlitelimab: Kymab
Amlitelimab SAR445229 (formerly KY1005) is a human monoclonal antibody that targets OX40L, a key regulator of the immune system. Amlitelimab is designed to rebalance the immune system by blocking inappropriate activation and proliferation of 'pro-inflammatory' effector T cells and promoting expansion of 'anti-inflammatory' regulatory T cells, without broad suppression of the immune system. It is believed this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In Phase I clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. It is believed the immune-modulating mechanism of Amlitelimab has broad potential therapeutic application in multiple diseases caused by immune dysregulation. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczema.

• BX 005: BiomX
BX005, a topical phage cocktail that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In preclinical in vitro studies, BX005 was shown to be active against over 90% of strains of S. aureus isolated from the skin of subjects from U.S. and Europe, including antibiotic resistant strains. Currently, the drug is being developed in the Phase I/II stage of clinical trial evaluation for the treatment of Atopic Dermatitis.

• LP 0145: LEO Pharma
LP 0145, is an anti-inflammatory monoclonal antibody under development for atopic dermatitis. Currently, the drug is being developed in the Phase II stage of clinical trial evaluation for the treatment of Eczemas.

Eczema Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Eczema. The companies which have their Eczema drug candidates in the most advanced stage, i.e. phase II include, LEO Pharma.

Learn more about the novel and emerging Eczema Pipeline Therapies, Eczema Companies, Eczema Ongoing Clinical Trials Analysis @ https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Eczema Pipeline Report
• Coverage- Global

• Eczema Companies- Kymab, BiomX, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc, Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, Ichnos Sciences, AOBiome, Kangstem Biotech, Devonian, VYNE therapeutics, BenevolentAI, Amytrx Therapeutics, Asana BioSciences, RAPT Therapeutics, Celgene Corporation, Shaperon, Allakos, KeyMed Biosciences, Ribon Therapeutics, Pfizer, Amgen, Evelo Biosciences, Novartis Pharmaceuticals, Oneness Biotech, Aclaris Therapeutics, Biosion, LEO Pharma, Principia Biopharma, Reistone Biopharma Company Limited, Botanix Pharmaceuticals, Qurient, Eli Lilly and Company, Suzhou Connect Biopharmaceuticals, Hoth Therapeutics, Kymera Therapeutics, KoBioLabs, and others.

• Eczema Pipeline Therapies- Amlitelimab, BX 005, LP 0145, GSK 1070806, AR 100, SCM AGH, SCD-044, BBI 02, Lebrikizumab, Benralizumab, UCB9741, ARQ-151, si-544, KHK-4083, ISB-830, B 244, FURESTEM-AD inj, PUR-0110, UCB-1381, FMX-114, BEN 2293, AMTX 100, Gusacitinib, RPT 193, CC 93538, HY-209, AK 002, CM 326, CM 310, RBN 3143, PF-07242813, Apremilast, EDP 1815, MEDI3506, Etrasimod, CMK 389, FB 825, ATI-1777, BSI 045B, LEO-152020, Rilzabrutinib, SHR0302, PRN-473, BTX-1204A, Q-301, Lebrikizumab, CBP 201, BioLexa, KT 474, KBL 697, and others.

• Eczema Segmentation: Phases, Molecule Type, Molecule Type, Route of Administration, Mechanism of Action

Table of Content
1. Introduction
2. Executive Summary
3. Eczema: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Eczema- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Amlitelimab: Kymab
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Eczema Key Companies
21. Eczema Key Products
22. Eczema- Unmet Needs
23. Eczema- Market Drivers and Barriers
24. Eczema- Future Perspectives and Conclusion
25. Eczema Analyst Views
26. Eczema Key Companies
27. Appendix

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Eczema drugs?
• How many Eczema drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Eczema?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Eczema therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Eczema and their status?
• What are the key designations that have been granted to the emerging drugs?

Dive deep into rich insights for new drugs for eczema treatment, visit Eczema Key Players and Therapies @ https://www.delveinsight.com/report-store/eczema-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.